|  | | 
 | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | | | () | |
|
| | | 
| |  | |
News Hub Callendar
| < July 2009 | | Su | M | T | W | T | F | S | | | 1 | 2 | 3 | 4 |
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 | |
|
| |
|
| | Articles by 'Altana Pharma AG' source |
|
|
|
ALTANA submitted New Drug Applications For Ciclesonide Nasal Spray in the U.S. and Canada
date: | category:
Major milestone in broadening the Ciclesonide product platform
| ALTANA continues growth course over the first half-year of 2005
date: | page: | | | category:
ALTANA AG (NYSE: AAA, FSE: ALT) increased first-half consolidated sales in 2005 by 5% to €1.55 billion. Adjusted for divestment effects in the Chemicals division, the operating growth was 7%.
| Fourth business unit for ALTANA Chemie
date: | page: | | category:
ALTANA Chemie AG, the Specialty Chemicals division of ALTANA AG (NYSE: AAA, FSE: ALT), has signed an agreement to acquire the ECKART GmbH & Co. KG, headquartered in Fürth Germany.
| ALTANA and Pfizer are terminating Daxas collaboration
date: | category:
ALTANA NYSE: AAA FSE: ALT and Pfizer have mutually agreed last night to terminate the Daxas® roflumilast collaboration as of June 30, 2005. Under the terms of their agreement, Pfizer will be returning all its rights in Daxas® to ALTANA.
| Top line results of first one-year COPD study with Daxas
date: | category:
Following the announcement of the termination of the Daxas® roflumilast collaboration with Pfizer, ALTANA NYSE: AAA, FSE: ALT discloses today the top line results of the first one-year COPD study of Daxas®.
| ALTANA opens new pharmaceutical production facility in Oranienburg
date: | page: | | category:
ALTANA AG NYSE: AAA, FSE: ALT today has opened a new pharmaceutical production facility in Oranienburg, in the presence of German Chancellor Gerhard Schröder and Minister President of the state of Brandenburg Matthias Platzeck.
| Study Shows Once-Daily Alvesco® Does Not Affect Short-Term Leg Growth In Children With Asthma
date: | category:
ALTANA Pharma announced today that a study published in the May issue of the Journal of Allergy and Clinical Immunology demonstrated that once-daily Alvesco® ciclesonide a new inhaled corticosteroid for the treatment of asthma
| Annual General Meeting 2005: ninth consecutive successful business year and dividend increase
date: | page: | category:
Shareholders of ALTANA AG NYSE: AAA, FSE: ALT approved all proposals made by the Management and Supervisory Boards at today’s Annual General Meeting in Frankfurt.
|
you can suggest new article source
Articles sources: |
|
